Organoid drug discovery
Organoid drug discovery screens compound libraries against three-dimensional human tissue grown from patient cells, so a drug's effect is measured on a model that behaves more like the patient than a flat cell line or an animal does.
Roughly nine in ten drugs that enter clinical trials fail, and a large share fail because the preclinical models did not predict human biology. Organoids attack that failure mode directly. They will not fix the attrition rate on their own, but as a more faithful model of solid-tumor biology they move the screen closer to the patient, which is where the commercial value sits.
Why screen on organoids instead of flat cells?
Two-dimensional cultures lose the geometry that governs how a real tumor responds: the cell-to-cell contacts, the oxygen and nutrient gradients, the dense matrix a drug has to penetrate. Organoids restore that three-dimensional context, and patient-derived organoids have been shown to track the actual treatment responses of the patients they came from.18 That predictive link is the whole proposition: a screen that anticipates the clinic rather than contradicting it.
The screening workflow
A patient sample becomes a biobank of organoids, plated into high-density multi-well formats, dosed by robotic liquid handlers across many concentrations, and read out by confocal imaging for cell death and microfluidic sensors for metabolic disruption. The result is a multi-point dose-response profile per compound per patient line, narrowing many candidates to the few worth advancing.
Targeted oncology pipelines
Three solid-tumor pipelines are where patient-derived organoids are furthest along, each with its own biology and its own reason to be hard:
- Patient-derived tumor organoids, the general approach of modeling a specific patient's cancer ex vivo to predict their drug response.
- Pancreatic ductal adenocarcinoma (PDAC), where a dense stromal barrier defeats most drugs and co-culture is essential.
- Glioblastoma (GBM), where tumor heterogeneity and the blood-brain barrier shape every screen.
- Tumor microenvironment models, the co-culture systems that reintroduce the cells a tumor hides behind.
Sourcing and compliance
Human-derived tissue carries obligations. Donor lines come through clinical partners with Institutional Review Board approval, and consent must explicitly cover reprogramming to iPSCs, differentiation into organoids, and use in commercial screening, not the narrower terms of an older biobank form. Lines are de-identified under secure identifiers, sequencing data is encrypted, and the facility runs at Biosafety Level 2. The deeper consent and data-rights questions this raises are treated as open problems on the bioethics page.
Request the capabilities brief
For screening collaborations or a technical capabilities brief, send a procurement inquiry. This is a neutral contact channel and does not affect the editorial content of this site.
References
- Vlachogiannis G, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-926. doi:10.1126/science.aao2774. Accessed 2026-06-12.
- Drost J, Clevers H. Organoids in cancer research. Nature Reviews Cancer. 2018;18(7):407-418. doi:10.1038/s41568-018-0007-6. Accessed 2026-06-12.